comparemela.com

Latest Breaking News On - Michelle pappanastos - Page 1 : comparemela.com

ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf LifeExtends.

United statesBoca ratonMichelle pappanastosAdam grossmanDrug administrationBiologics incBusiness development corporate strategyProduct administration to patientsExchange commissionRoom temperatureStorage conditionsAny point duringMonth approved shelfPrior room temperature storage allowanceImproved inventory managementProduct administration

ADMA Biologics Announces CFO Transition

ADMA Biologics Announces CFO Transition
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBoca ratonAdam grossmanBrian lenzMichelle pappanastosBiologics incDrug administrationExchange commissionBusiness developmentExecutive vice presidentChief financial officerGeneral managerChief executiveInterim chief financial officerChief financialUnited states food

ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITD.

Boca ratonUnited statesAdam grossmanMichelle pappanastosBiologics incDrug administrationExchange commissionBusiness developmentNet incomeRevenue guidance increasedMore thanIncome guidance increasedGrowth opportunities targeting manufacturingNew pipeline hyperimmune globulinAdvance duringCall scheduled

ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28.02.2024 - 4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net .

United statesBoca ratonAdam grossmanMichelle pappanastosBiologics incBusiness developmentExchange commissionDrug administrationRevenue guidance increasedMore thanIncome guidance increasedGrowth opportunities targeting manufacturingNew pipeline hyperimmune globulinAdvance duringCall scheduledChief executive officer

ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production ProcessesADMA Successfully Utilized ADMAlytics’ New Capabilities for.

United statesBoca ratonAdam grossmanMichelle pappanastosBiologics incCompany admalyticsBusiness development corporate strategyDrug administrationExchange commissionInformation technologyCombines generativeMachine learningOptimize productionNew capabilitiesFirst timeRealize efficiency improvements

vimarsana © 2020. All Rights Reserved.